Please login to the form below

Not currently logged in
Email:
Password:

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

Dr Kenneth Sommerville has left his role at pharma giant Pfizer to join GW Pharma.

Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.

At GW he will assume in the newly-created role of VP, clinical research, where he will lead clinical development, medical affairs, and regulatory activities related to the company's work in epilepsy, pain and other diseases.

GW's research is focused on the development of cannabinoids. This includes Sativex, which became the world's first plant-derived cannabinoid prescription drug when it was approved for multiple sclerosis in Canada and the European Union in 2010. It is also in clinical trials for other indications, including cancer pain.

"This is an exciting time to be joining GW, with a number of important products currently under development for patients in the US including Sativex and Epidiolex,” said Dr Sommerville.

8th May 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics